Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Foltynie

Showing results (1-10 of 258) with videos related to

Pageof 26
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|June 27, 2013
CommentaryThomas Foltynie
Cell Stem Cell|January 5, 2024
Scaling up GMP-grade dopaminergic cells for Parkinson's diseaseThomas Foltynie
The Lancet. Neurology|October 20, 2019
Glycolysis as a therapeutic target for Parkinson's diseaseThomas Foltynie
The Journal of Clinical Investigation|February 18, 2015
Can Parkinson's disease be cured by stimulating neurogenesis?Thomas Foltynie
Lancet (London, England)|May 28, 2026
Prasinezumab: what have we learned from PASADENA and PADOVA?Thomas Foltynie
Neuropharmacology|October 17, 2021
Disease modifying therapies III: Novel targetsNirosen Vijiaratnam, Thomas Foltynie
Drug Discovery Today|February 7, 2016
The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of actionDilan Athauda, Thomas Foltynie
Neuropharmacology|September 21, 2017
Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's diseaseDilan Athauda, Thomas Foltynie
Drugs|May 9, 2020
Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson's DiseaseNirosen Vijiaratnam, Thomas Foltynie
Parkinsonism & Related Disorders|August 9, 2016
Challenges in detecting disease modification in Parkinson's disease clinical trialsDilan Athauda, Thomas Foltynie
Pageof 26

Showing results (1-10 of 258) with videos related to

Sort By:
Pageof 26
Movement Disorders : Official Journal of the Movement Disorder Society|June 27, 2013
CommentaryThomas Foltynie
Cell Stem Cell|January 5, 2024
Scaling up GMP-grade dopaminergic cells for Parkinson's diseaseThomas Foltynie
The Lancet. Neurology|October 20, 2019
Glycolysis as a therapeutic target for Parkinson's diseaseThomas Foltynie
The Journal of Clinical Investigation|February 18, 2015
Can Parkinson's disease be cured by stimulating neurogenesis?Thomas Foltynie
Lancet (London, England)|May 28, 2026
Prasinezumab: what have we learned from PASADENA and PADOVA?Thomas Foltynie
Neuropharmacology|October 17, 2021
Disease modifying therapies III: Novel targetsNirosen Vijiaratnam, Thomas Foltynie
Drug Discovery Today|February 7, 2016
The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of actionDilan Athauda, Thomas Foltynie
Neuropharmacology|September 21, 2017
Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's diseaseDilan Athauda, Thomas Foltynie
Drugs|May 9, 2020
Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson's DiseaseNirosen Vijiaratnam, Thomas Foltynie
Parkinsonism & Related Disorders|August 9, 2016
Challenges in detecting disease modification in Parkinson's disease clinical trialsDilan Athauda, Thomas Foltynie
Pageof 26